Related Experiment Video
Updated: Oct 10, 2025
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Statins for secondary prevention and major adverse events after coronary artery bypass grafting
Emily Pan1, Susanne J Nielsen2, Ari Mennander3
1Department of Surgery and Clinical Medicine, University of Turku, Turku, Finland; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Insights
Ongoing statin use significantly reduces adverse events and mortality after coronary artery bypass grafting (CABG). Maintaining statin therapy is crucial for improving long-term outcomes in CABG patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Public Health
Background:
- Coronary artery bypass grafting (CABG) is a major surgical procedure for advanced coronary artery disease.
- Secondary prevention strategies are vital for improving long-term outcomes post-CABG.
- The role of statin therapy in mitigating long-term adverse events after CABG requires comprehensive evaluation.
Purpose of the Study:
- To assess the association between statin use and long-term adverse cardiovascular events following CABG.
- To investigate the impact of statin therapy on mortality and other adverse outcomes in a large cohort of CABG patients.
- To determine if statin dosage influences the risk reduction of adverse events post-CABG.
Main Methods:
- A nationwide cohort study including 35,193 patients undergoing first-time isolated CABG in Sweden (2006-2017).
- Data linkage between the SWEDEHEART registry and other national registries for comprehensive patient information.
- Multivariable Cox regression models were employed to analyze the association between statin treatment and outcomes, adjusting for confounders.
Main Results:
- Ongoing statin treatment was associated with a significant reduction in major adverse cardiovascular events (MACE) (aHR 0.56).
- Statin use markedly reduced all-cause mortality (aHR 0.53), cardiovascular death (aHR 0.54), myocardial infarction (aHR 0.61), and stroke (aHR 0.66).
- Significant risk reductions were also observed for new revascularization, new angiography, and dementia, irrespective of statin dose.
Conclusions:
- Ongoing statin use is strongly associated with a substantial decrease in adverse events and mortality after CABG.
- Initiating and consistently maintaining statin medication is a critical component of post-CABG care.
- Statin therapy plays an essential role in improving the long-term prognosis for patients following coronary artery bypass grafting.
Objective:
The objective of this study was to evaluate the association of statin use after coronary artery bypass grafting (CABG) and long-term adverse events in a large population-based, nationwide cohort.
Methods:
All 35,193 patients who underwent first-time isolated CABG in Sweden from 2006 to 2017 and survived at least 6 months after surgery were included. Individual patient data from the Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) and 4 other nationwide registries were merged. Multivariable Cox regression models adjusted for age, sex, comorbidities, and time-updated treatment with other secondary preventive medications were used to evaluate the associations between statin treatment and outcomes. The primary end point was major adverse cardiovascular events (MACE). Median follow-up time to MACE was 5.3 (interquartile range, 2.5-8.2) years.
Results:
Statins were dispensed to 95.7% of the patients six months after discharge and to 78.9% after 10 years. At baseline, 1.4% of patients were prescribed low-, 57.6% intermediate-, and 36.7% high-dose statins. Ongoing statin treatment was associated with markedly reduced risk of MACE (adjusted hazard ratio [aHR], 0.56 [95% CI, 0.53-0.59]), all-cause mortality (aHR, 0.53 [95% CI, 0.50-0.56]), cardiovascular death (aHR, 0.54 [95% CI, 0.50-0.59]), myocardial infarction (aHR, 0.61 [95% CI, 0.55-0.69]), stroke (aHR, 0.66 [95% CI, 0.59-0.73]), new revascularization (aHR, 0.79 [95% CI, 0.70-0.88]), new angiography (aHR, 0.81 [95% CI, 0.74-0.88]), and dementia (aHR, 0.74 [95% CI, 0.65-0.85]; all P < .01), irrespective of the statin dose.
Conclusions:
Ongoing statin use was associated with a markedly reduced incidence of adverse events and mortality after CABG. Initiating and maintaining statin medication is essential in CABG patients.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:27Coronary Artery Disease V: Interprofessional Care
01:26Atherosclerosis III: Management
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:26Angina IV: Management